AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04148560 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Tests of the validity of the RFPM and SmartIntake app.
Description: Participants who enroll will be trained in using the RFPM/SmartIntake app and a food record and will complete the Food Intake Assessment Preference Survey. They will also use both methods to estimate intake during a simulated lab-based meal (they will not eat during this simulated meal). They will be dosed with DLW at this visit and will use the RFPM for the subsequent 1-2 days to get accustomed to using the method, with the following three days comprising the data collection period.
Study NCT01228500 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PriMatrix
Description: Dermal Repair Scaffold
Study NCT03035942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 8 mg (made up to 5 mL with normal saline) will be drawn into each syringe which will be offered to the anesthesia provider after the opaque envelope was opened and administered immediately after spinal anesthesia was performed.
Study NCT03035942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondansetron 4 mg (made up to 5 mL with normal saline) will be drawn into each syringe which will be offered to the anesthesia provider after the opaque envelope was opened and administered immediately after spinal anesthesia was performed.
Study NCT03035942 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Normal saline (5 mL total volume) will be drawn into each syringe which will be offered to the anesthesia provider after the opaque envelope was opened and administered immediately after spinal anesthesia was performed.
Study NCT04183491 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a
Description: Interferon beta-1a 7.5 µg administered IM
Study NCT04183491 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a
Description: Interferon beta-1a 15 µg administered IM
Study NCT04183491 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a
Description: Interferon beta-1a 30 µg administered IM
Study NCT04214886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is is an anti-cancer drug acting as an alkylating agent that is used to treat leukemia and lymphoma cancers.
Study NCT04214886 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-CD34 CAR transduced T cells
Description: CD19-CD34 CAR transduced T cells are the subject's own immune cells that target B cell markers on cancer cells.
Study NCT02023021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Patients firstly receive nab-paclitaxel 100 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
Study NCT02023021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Patients secondly receive gemcitabine 1000 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
Study NCT00376805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: administered intravenously 25 mg/m\^2 times 5 doses
Study NCT00376805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: administered intravenously 60 mg/kg days times 2 doses.
Study NCT00376805 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation
Description: 200 cGy (gray) on day -1
Study NCT00376805 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natural killer cell infusion
Description: Infused cell dose is within the range of 1.5-8.0 x 10\^7/kg. Cell counts are based on total cells infused after the activation culture and washing determined on the morning of infusion.
Study NCT00376805 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: administered subcutaneously (10 MU) 3 times per week for 6 doses
Study NCT00526110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 2.2 Gm/m\^2 IV over 48 hours on Day 1.
Study NCT00526110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 20 mg/m\^2 IV over 60 minutes
Study NCT00526110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m\^2 IV over 120 minutes on Day 1.
Study NCT03693313 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CrossFit Kids exercise program
Description: Participants will be actively participating in a 14 week twice weekly CrossFit Kids exercise program.
Study NCT03693313 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CrossFit Kids exercise program
Description: Participants will be actively participating in a 14 week twice weekly CrossFit Kids exercise program.
Study NCT03354832 — intervention group
Intervention type: OTHER
Intervention: Foetal death
Description: A midwife is in charge to interview the mother during the month following the lost of her infant.
Study NCT03354832 — intervention group
Intervention type: OTHER
Intervention: New-born death
Description: A midwife is in charge to interview the mother during the month following the lost of her infant.
Study NCT03354832 — intervention group
Intervention type: OTHER
Intervention: Birth control for foetal death
Description: A midwife is in charge to interview the mother during her hospital stay
Study NCT03354832 — intervention group
Intervention type: OTHER
Intervention: Birth control for new-born death
Description: A midwife is in charge to interview the mother during her hospital stay
Study NCT03286777 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mannitol and silicon dioxide capsules
Study NCT03286777 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Native 6-prenylnaringenin
Description: 250 mg native 6-PN plus mannitol and silicon dioxide capsules
Study NCT03286777 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micellar 6-prenylnaringenin
Description: 250 mg 6-PN in a micellar formulation with Tween-80 as adjuvant capsules
Study NCT05280327 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Application
Description: The pregnant women in the experimental group were played by the researcher during the active and transitional phases of labor with virtual reality glasses, which were designed for research and included methods used to cope with labor pain
Study NCT02926092 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Observation
Description: Observation of progression of disease over time
Study NCT01175200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: antiplatelet agent
Study NCT01175200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: antiplatelet agent
Study NCT01175200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: proton pum inhibitor
Study NCT03784027 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CamAPS FX
Description: CamAPS FX closed loop system comprises:~* Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)~* Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)~* An Android smartphone hosting CamAPS FX app with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump and glucose sensor~* Cloud upload system to monitor CGM/insulin data
Study NCT03784027 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sensor augmented therapy
Description: Study insulin pump and study CGM.
Study NCT01175200 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo comparator similar to lansoprazole
Study NCT01605487 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rupatadine
Description: Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days
Study NCT01605487 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rupatadine
Description: Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days,then 14 days washout period; Placebo 4 Tab once daily during 7 days
Study NCT01605487 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rupatadine
Description: Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days
Study NCT01605487 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rupatadine
Description: Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days,then 14 days washout period; Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days
Study NCT01605487 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rupatadine
Description: Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days
Study NCT01605487 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rupatadine
Description: Rupatadine in Tab. 10mg: 4 Tab. once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Placebo 4 Tab once daily during 7 days
Study NCT03514680 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CIPN Assessment and Management Algorithm
Description: The revised algorithm incorporates evidence-based CIPN assessment and management strategies and standardized CIPN/pain patient-reported outcomes measures. In terms of processes, trained study staff will administer the screening questionnaires (e.g., PRO-CTCAE, 0 - 10 numerical rating scale of worst CIPN pain intensity) to consented patients before their clinician visit (e.g., in the waiting room). Following patient completion of the screening questionnaires, study staff will provide the clinicians with a color-coded summary of the patients' responses to the screening questionnaires and the CIPN assessment and management algorithm. Clinicians may then use the algorithm at their discretion to guide the assessment and management of their patients' CIPN symptoms
Study NCT05336825 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CO2 laser
Description: Mona Lisa CO2 laser
Study NCT05336825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine patch 5%
Description: lidocaine
Study NCT05289583 — intervention group
Intervention type: BEHAVIORAL
Intervention: Dialectical Behavior Therapy
Description: DBT is a cognitive-behavioral treatment program that was developed to treat suicidal Patients with BPD (Linehan, 1993).
Study NCT04551001 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cold forcep polypectomy
Description: Removal of appropriate polyps using cold forceps until no polyp visible under white light. Two additional biopsies performed at margins of polypectomy site.
Study NCT04551001 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cold snare polypectomy
Description: Removal of appropriate polyps using cold snare until no polyp visible under white light. Two additional biopsies performed at margins of polypectomy site.
Study NCT04082910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: Metoprolol was given in patients who received CAR T cell therapy for CRS control or CRS precaution.
Study NCT04082910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoprolol, infliximab, etanercept, tocilizumab and/or other agents
Description: During the term of metoprolol use, antibodies (infliximab, etanercept and tocilizumab) and/or other agents were not completely limited to be used under the consideration of clinical requirement for sufficient control of continuously progressed CRS.
Study NCT00966719 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lactation Consultant support
Description: Meeting with lactation consultant once while in hospital and up to 3 times after discharge, in addition to current standard of care for jaundice.
Study NCT01842594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus and hydroxychloroquine
Description: Both hydroxychloroquine 200 mg/tab and sirolimus 1 mg/tab are pills each are taken 2 tablet orally QD for 2 cycles .~Each treatment cycle is 28 days.
Study NCT00682136 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: US-Guided Ropivacaine TAP Block
Description: Bilateral injection of local anaesthetic into the Transversus Abdominis plane, guided by ultrasound.
Study NCT03099941 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biofeedback
Description: The aim of this study is to investigate effects of a biofeedback application that is alternative to physical therapist feedback in core stabilization training of patients with CNLBP.
Study NCT03099941 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback
Description: The aim of this study is to investigate effects of a biofeedback application that is alternative to physical therapist feedback in core stabilization training of patients with CNLBP.
Study NCT00768404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topirmate and Phentermine
Description: A single oral dose of the combination product VI-0521 (15 mg phentermine and 92 mg topiramate) will be administered with 240 mL of water at hour 0.
Study NCT03230812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carnitene (L-Carnitine or Levocarnitine)
Description: All subjects will undergo oral Carnitene (L-Carnitine or levocarnitine) supplementation for 96 days.The total dosage of L-carnitine per day will be 2970mg. Consumption of the chewing tablets will be divided over the day. Intake of these chewing tablets will be during breakfast (990mg), lunch (990mg) and during diner (990mg). Since the chewing tablets are only available in concentrations of 330mg, participants have to consume 3 chewing tablets per meal, a total of 9 chewing tablets each day.
Study NCT03378089 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: No narcotic or anti-emetic therapy will be administered for at least 2 hours prior to music therapy session. Music therapy sessions will be administered by a board certified music therapist (MT-BC) and last approximately 45 minutes. Involvement in sessions will be based on therapist and patient availability.
Study NCT03378089 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No Music Therapy
Description: Participants will fill the same 45 minute period in any way they choose; however, they will be asked to refrain from listening to recorded music during this time.
Study NCT02106247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1181181 high dose
Description: two tablet
Study NCT02106247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1181181 low dose
Description: one tablet
Study NCT02106247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: tablet
Study NCT01776671 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gralise
Description: Titration starting 300 mg/day up to 1800 mg/day over 2 weeks
Study NCT03724656 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture treatment
Description: TAES treatment 30 minutes before induction of anesthesia. Bilateral Neiguan（PC6）, bilateral Zusanli（ST36）and bilateral Hegu （LI4）point were selected by electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China).After Deqi, electroacupuncture stimulation apparatus is connected and maintained until the end of operation.
Study NCT03724656 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture treatment
Description: Participants in the sham acupuncture group received shallow needling (0.30mm×25mm) at bilateral sham points(nonacupoints located 5cm beside acupoints, about 20mm). The control group was treated with non-acupoint shallow acupuncture method and the needling depth was less than 2 mm. At the same time, the manual stimulation and Deqi was avoided.
Study NCT04214431 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Childbirth Education
Description: 8-week mindfulness-based childbirth education
Study NCT00477269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Study NCT04183491 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon beta-1a
Description: Peginterferon beta-1a 31.25 µg administered SC
Study NCT04183491 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon beta-1a
Description: Peginterferon beta-1a 62.5 µg administered SC
Study NCT03414684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin interferes with the development of the genetic material in a cell, which will cause the cancer cells to die.
Study NCT03414684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin interferes with the development of the genetic material in a cell, which will cause the cancer cells to die.
Study NCT02734446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reuterin D3 drops
Description: 5 drops/day for 3 months
Study NCT02734446 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 drops/day for 3 months
Study NCT04242615 — intervention group
Intervention type: OTHER
Intervention: Prognostic score
Study NCT04389567 — intervention group
Intervention type: DRUG
Intervention: Famotidine
Description: Use of oral Famotidine.
Study NCT00477269 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04418336 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Pilonidal sinus treatment (EPSIT) versus Sinus Laser Closure (SiLaC) versus lay open technique
Description: Endoscopic Pilonidal sinus treatment (EPSIT) versus Sinus Laser Closure (SiLaC) versus lay open technique in sacrococcygeal Pilonidal sinus treatment
Study NCT02989051 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Restrictive fluid regimen
Description: In this treatment arm, patients will receive a maximal daily fluid intake of 70% of normal requirements (for a healthy child).
Study NCT02989051 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Liberal fluid regimen
Description: This is considered current standard clinical treatment, wherein patients will receive a fluid regimen of >85% of normal fluid recommendations (for a healthy child).
Study NCT03186391 — intervention group
Intervention type: OTHER
Intervention: Data collected
Description: Use the data collected during a usual consultation to study the relationship between different parameters (rest pressure ...) and imaging
Study NCT05764031 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical pilates exercise
Description: Clinical pilates is an exercise modality in which postural muscles are worked out with various body movements, and involves multi-muscle synergies that improve spinal stabilization, flexibility and endurance.
Study NCT05764031 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Aerobic exercise (also known as endurance activities, cardio or cardio-respiratory exercise) is physical exercise of low to high intensity that depends primarily on the aerobic energy-generating process.
Study NCT02011490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sugammadex
Description: sugammadex 4 mg/kg IV bolus
Study NCT04086446 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high-definition transcranial direct current stimulation
Description: The tDCS device will deliver a direct current of 1.5mA during 20 minutes. Cathode electrode will be localized in front of the right OFC on the Fp2 point according to the EEG international reference. Four anode electrodes will be placed around FP2 (i.e. Fpz, AFz, AF4, AF8)
Study NCT04086446 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: The same procedure will be applied except that the tDCS device will only deliver a current stimulation for the first and last 15 seconds.
Study NCT03783104 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: B12 Supplement
Description: Differential doses of vitamin B 12 supplementation in a two-armed randomised controlled trial
Study NCT03783104 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: B12 Supplement
Description: Differential doses of vitamin B 12 supplementation in a two-armed randomised controlled trial
Study NCT01071356 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive MI
Description: Weekly individual therapy sessions over 9 weeks (Intensive MI condition) consisting of supportive and directive interventions. The control condition consists on a single session of MI and nutritional education.